Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4
Check this box if no longer subject to Section 16. Form 4 or Form 5				Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP												3235-0287
Instruction 1(b).							or Section 30(h) of the Investment Company Act of 1940									0.5
1. Name and Address of Reporting Person* BRADSHER NEAL C					2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [ LCTX ]									X
(Last) (First) (Middle) C/O BROADWOOD CAPITAL INC.				3. Date of Earliest Transaction (Month/Day/Year) 07/01/2016								Other (specify below) below)
				4. If Amendment, Date of Original Filed (Month/Day/Year) 07/02/2020								6. Individual or Joint/Group Filing (Check Applicable Line)
(Street) NEW YORK NY 10019												X Form filed by One Reporting Person Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) Date					if any			Transaction Code (Instr. 8)								7. Nature of Indirect Beneficial Ownership (Instr. 4)
									(A) or Amount (D)		Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. 3. Transaction 3A. Deemed Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Price of Derivative Security		4. 8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securities 4)		8. Price of Derivative Security (Instr. 5) Owned		10. Form:		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date			Title	Amount or Number of Shares
\$1.67(1)							(2)			SHARES					D
\$2.55(1)							(2)			SHARES					D
\$2.2(1)							(2)			SHARES					D
		FORM 4 obligations may continue. See (State)	142 WEST 57TH STREET, 11TH FLOOR (Zip)	(Month/Day/Year)	2. Transaction (Month/Day/Year) Code V	Transaction Code (Instr.	2A. Deemed	3. Execution Date, (Month/Day/Year)	Code V Exercisable	Expiration Date	06/30/2023 COMMON 06/30/2022 COMMON 06/30/2021 COMMON	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 4. Securities Acquired (A) or (e.g., puts, calls, warrants, options, convertible securities) 7. Title and Amount Underlying Derivative Security (Instr. 3 and 49,440 24,720 24,720	UNITED STATES SECURITIES AND EXCHANGE COMMISSION X Disposed Of (D) (Instr. 3, 4 and 5)	(Check all applicable) Director Officer (give title 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) (Instr. 4)	9. Number of derivative Securities Beneficially Following Reported Transaction(s) 49,440 24,720 24,720	OMB APPROVAL OMB Number: Estimated average burden hours per response: 5. Relationship of Reporting Person(s) to Issuer 10% Owner 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Ownership Direct (D) or Indirect (I) (Instr. 4)

Explanation of Responses:

1. This amendment to the Form 4 filed by Neal C. Bradsher on July 2, 2020 (the "July 2020 Form 4") is being made solely to correct the exercise price of certain options to purchase common shares of Lineage Cell Therapeutics, Inc. (the "Issuer") currently held by Mr. Bradsher (collectively, the "Stock Options"). In particular, the respective exercise prices of these reported Stock Options were adjusted following the distribution of shares of common stock of AgeX Therapeutics, Inc. to the Issuer's shareholders on November 28, 2018 (the "AgeX Distribution"). The number of Stock Options was properly adjusted at the time of the AgeX Distribution; however, the exercise prices of these reported Stock Options were not properly adjusted. For the avoidance of doubt, none of the Stock Options reported in this Form 4 amendment or the July 2020 Form 4 filing have been exercised.

2. These options are currently exercisable.

/s/ Neal C. Bradsher 02/16/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.